Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
multiple myeloma
Pharma
FDA advisers back new endpoint for myeloma approvals
After experts reviewed arguments in favor of a surrogate endpoint to support approvals, myeloma drug developers may soon have a new R&D pathway.
Angus Liu
Apr 12, 2024 4:06pm
FDA review bodes well for MRD-based myeloma approvals
Apr 10, 2024 11:30am
FDA weighs another approvable myeloma endpoint. What's at stake?
Apr 9, 2024 9:00am
J&J, Legend's Carvykti quickly leaps ahead of BMS' rival CAR-T
Apr 8, 2024 8:30am
BMS' Abecma wins earlier myeloma nod with updated boxed warning
Apr 5, 2024 11:46am
UPDATED: FDA advisers back Carvykti, Abecma in earlier myeloma
Mar 15, 2024 1:58pm